We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Wine-Related Cancer Treatment Shows Promise Against Neuroblastomas

By LabMedica International staff writers
Posted on 12 Mar 2009
Print article
Resveratrol--the intriguing substance that seems to make red wine heart-healthy--is being proposed for clinical trials later in 2009 as a treatment against neuroblastoma, a type of cancer that affects infants and young children.

Dr. Arthur Polans, professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health (UW; Madison, USA) and the UW Paul P. Carbone Comprehensive Cancer Center, has been studying the substance for about five years, and has been using it successfully to treat several types of cancer in mice. His research group has applied for permission to use it to treat neuroblastoma, a nervous-system cancer that mostly affects infants and children.

"Resveratrol is a promising treatment for young children because it's not toxic to healthy cells, only to cancer cells,'' Dr. Polans said. "How do you treat infants without causing other problems in the years to come? That is the kind of question that intrigues us.”

Because it seems to kill cancer kills while leaving healthy tissue alone, resveratrol is also being looked at to treat ocular or uveal melanoma, a cancer of the eye that can lie dormant for many years before metastasizing and becoming fatal. So far, there are no good treatments for melanoma that begins in the colored tissues of the eye; it doesn't respond the same way as melanoma that begins in the skin. "It's one of those rotten cancers,'' Dr. Polans noted. "We don't know what causes it and we don't know how to treat it effectively.”

While the cancers are very different, adults who develop melanoma of the eye have something in common with babies who develop neuroblastoma--they may live for a long time after their diagnosis, so potential treatments shouldn't cause other health problems.

"What neuroblastoma and uveal melanoma have in common is the factor of time,” said Dr. Polans. "Ideally, you'd like to be able to treat them aggressively at first, and then treat them with lower doses of a non-toxic compound over time. Otherwise, you run the risk of damage to vital organs or an increase in secondary tumors.”

So far, the Polans lab has shown that resveratrol shrinks tumors and kills malignant cells in five types of cancer: skin melanoma, breast cancer, neuroblastoma, ocular melanoma and retinoblastoma. A poster outside Dr. Polans' office shows a mouse with a large neuroblastoma tumor that is then shrunken to nothing by resveratrol. "Mice that were treated with resveratrol are healthy, gain weight, and don't seem to have side effects,'' he said, "but when you look at the cancer cells, they're dying.”

Dr. Polans' lab has also done a lot of essential research on resveratrol, developing new forms of the compound that are more potent, and active in the body for longer than the common forms of the substance.

If it shows to be effective, resveratrol will join a large class of cancer-fighting compounds derived from plants, including taxol, which comes from yew trees, and etopside, derived from the mayapple. Resveratrol, which can be derived from grape skins, is also seen as the substance at work in the so-called "French Paradox,'' in which French hearts stay healthy (due to drinking red wine) in spite of all the high fat foods consumed.

"About 70% of new chemotherapeutics are derived from natural products or based on their structures,'' concluded Dr. Polans. "There's a lot of interest worldwide in finding new substances from plants and other natural sources, including microbes from the soil and a variety of species from the ocean.”

Related Links:

University of Wisconsin School of Medicine and Public Health


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)

Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections

Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.